CSL

CSL Bioplasma has four Product Liaison Specialists in Australia and one in New Zealand who provide information and supporting reference materials about our products to specialists, nurses and hospital blood bank scientists.

This service supports the appropriate use of products manufactured under the Plasma Products Agreement with the National Blood Authority in Australia and the Manufacturing Agreement with the New Zealand Blood Service (NZBS).

The information provided includes changes to registered indications and storage conditions, registered dose, administration, and known side effects. This Product Liaison Team service is particularly valued by new medical staff, or those who irregularly use these products, and helps to underpin patient welfare.

The Product Liaison Team also provides information about the fractionation processes used at our Broadmeadows facility in Melbourne and the safety profile of the plasma products we manufacture. This covers the multiple and overlapping procedures and processes to optimise product safety including donor deferral policies used by the blood services, testing of every donation prior to use, and the manufacturing process for every product with at least two dedicated steps solely to optimise pathogen safety.

CSL Bioplasma works with appropriately qualified experts at the Australian Red Cross Blood Service (ARCBS) and the NZBS to develop information which can be used by health care professionals during discussions with their patients prior to the administration of our products.

The team also provides information to donor service staff of the ARCBS and NZBS about products manufactured from donations and the conditions they treat. This empowers staff to communicate their knowledge to voluntary and non-remunerated donors - the people who the blood supplies of Australia and New Zealand rely on.